Growth Hormone Treatment May Have Transmitted Alzheimer’s to Children, Study Warns

A now discontinued hormone therapy that contained contaminated cadaver tissue may have transmitted degenerative brain disorders to patients.

Alzheimer’s disease and other degenerative brain disorders that are normally inherited or develop sporadically later in life may be transmissible in certain circumstances, according to the findings of new research.

A team of U.K. researchers from the National Hospital for Neurology and Neurosurgery and the UK Dementia Research Institute at UCL in London indicate patients who received contaminated growth hormone treatments as children may be at risk of developing Alzheimer’s disease, dementia, or other symptoms seen among those with neurodegenerative disorders.

Alzheimer’s disease progressively destroys brain cells and tissue, which causes deterioration of memory, thinking, and social skills. The widespread and degenerative disease is the most common form of dementia, or memory loss, and eventually interferes with daily functioning.

Do You Know About...

Childhood Diabetes Lawsuits Against Junk Food Industry

Lawyers are now pursuing financial compensation for families of children diagnosed with Type II diabetes, fatty liver disease and other chronic illnesses caused by addictive and harmful substances in ultra-processed foods.

Learn More

In this new study, researchers indicate that between 1959 and 1985, at least 1,848 patients in the United Kingdom were treated with human growth hormones extracted from the pituitary glands of deceased donors, known as human cadaveric pituitary-derived growth hormone (c-hGH). Patients received these hormone injections several times per week, over the course of several months or years, to treat severe short stature and other conditions caused by hormone deficiencies.

The treatments were discontinued in 1985, after at least one patient treated with c-hGH died from iatrogenic Creutzfeldt–Jakob disease (iCJD), a rare but rapidly progressive and degenerative brain disease that is acquired when infectious brain proteins are accidentally transmitted to patients during medical or surgical procedures that use cadaveric tissue.

Researchers later tested archived batches of the c-hGH treatments and found they were contaminated with measurable quantities of AB seeding; precursors to developing Alzheimer’s disease.

According to findings published this week in the medical journal Nature Medicine, at least 200 cases of iCJD have been reported worldwide as a result of the contaminated treatments.

Cognitive Impairment Linked to Growth Hormone Exposure

The researchers analyzed the medical history of eight individuals treated with c-hGH injections during different stages of childhood, who were referred to the National Prion Clinic (NPC) in the UK, which studies those diagnosed or at risk of developing brain diseases from the therapies.

At least five patients exhibited symptoms consistent with those seen with early-onset dementia, including progressive cognitive impairment, which developed between 38 and 55 years of age, between three and four decades after c-hGH exposure. Three of the five patients had been diagnosed with Alzheimer’s disease prior to be being referred to the clinic, and the other two patients presented symptoms seen among those with the disease, including memory loss, trouble communicating, and changes in behavior or personality.

Researchers reviewed brain scans of the patients, which showed progressive loss of brain tissue volume that are consistent with neurodegenerative diseases. Three of the eight study participants died, and autopsies revealed accumulations of infectious AB deposits in the brain, similar to those seen among those suffering from Alzheimer’s disease.

Genetic testing ruled out any potential genetic factors for developing adult-onset brain disorders, and the patients’ ages meant sporadic early-onset was unlikely, leading researchers to determine the new and progressive cognitive disturbances seen among the patients were the result of repeated c-hGH exposure. Among the study participants, at least four c-hGH recipients were diagnosed with confirmed Alzheimer’s disease, five met the standard definition for dementia, two with a clinical diagnosis of dementia were suspected to also have Alzheimer’s, and one had mild cognitive impairment, according to the findings.

The findings suggest Alzheimer’s disease can be transmitted in certain circumstances, such as during medical procedures. While there is no evidence that it can be transmitted to others during daily activities, researchers indicate further studies are needed to analyze exactly how this disease spreads. Researchers also indicate the findings warrant further preventative measures to avoid medically transmitted brain diseases, such as ensuring surgical instruments and other medical treatments are properly disinfected.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Depo-Provera Brain Tumor Symptoms Create Lifelong Meningioma Fears Among Women
Depo-Provera Brain Tumor Symptoms Create Lifelong Meningioma Fears Among Women (Posted 3 days ago)

Women across the U.S. are now pursuing product liability lawsuits and medical monitoring class action claims to secure compensation for potential brain tumor symptoms and side effects linked to the use of Depo-Provera.

Court Asked To Establish Valsartan Settlement Fund and Appoint Administrator
Court Asked To Establish Valsartan Settlement Fund and Appoint Administrator (Posted 4 days ago)

The judge presiding over the federal Valsartan lawsuits has been asked to approve the creation of a qualified settlement fund, as well as appoint an administrator and custodian for funds that will be paid to former users of the recalled hypertension drugs who have developed cancer.